['tourette syndrome']
['dronabinol and palmitoylethanolamide']

        Inclusion Criteria:

          -  Adult between 18-60 years of age

          -  Meet DSM-5 criteria for the diagnosis of Tourette syndrome

          -  Significant current tic symptoms: YGTSS total tic score greater than or equal to 22 at
             baseline

          -  On stable psychiatric medication regimen for a minimum of 4 weeks prior to beginning
             the trial

          -  Accepted method of birth control

        Exclusion Criteria:

          -  Comorbid bipolar disorder, psychotic disorder, substance use disorder, developmental
             disorder or intellectual disability (IQ<70)

          -  Recent change (less than 4 weeks) in other medications that have potential effects on
             tic severity (such as alpha-2 agonists (guanfacine, clonidine or prazosin), SSRIs,
             clomipramine, naltrexone, lithium, anxiolytics, topiramate, baclofen etc.). Medication
             change is defined to include dose changes or medication discontinuation.

          -  Recent change in behavioral treatment for Tourette syndrome or comorbid conditions
             (i.e. OCD) within the last 4 weeks or initiation of behavioral therapy for tics within
             the last 12 weeks.

          -  Taking any co-medications (over the counter or prescription), food
             supplements/additives which can have a drug interaction with dronabinol or PEA.

          -  Positive pregnancy test or drug screening test

          -  History of cannabis dependence

          -  Significant Medical Comorbidity

          -  History of hypersensitivity to any cannabinoid or sesame oil
      